 |
|
|
| |
DISTRIBUTION OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) IN PLASMA, MUCOSAL TISSUES, AND ASSOCIATED FLUIDS AFTER A SINGLE ULTRASOUND-GUIDED INTRAMUSCULAR (IM) INJECTION IN HEALTHY ADULT PARTICIPANTS
|
| |
| |
HIVR4P 2021 (Virtual event); 27-28 January & 3-4 February 2021
Reported by Jules Levin
Ethel D. Weld,1 Jafar Sadik Shaik,2 Stacey Edick,3 Edward Fuchs,1 Sharon Riddler,3 Mark Marzinke,1 Ronald D'Amico,4 Kalpana Bakshi,2 Yu Lou,5 Craig Hendrix,1 Kelong Han,2 Susan L. Ford,6
David Margolis,4 William Spreen,4 Parul Patel4
1Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2GlaxoSmithKline, Collegeville, PA, USA; 3University of Pittsburgh, Pittsburgh, PA, USA; 4ViiV Healthcare, Research Triangle Park, NC, USA; 5Precision Biosciences, Durham, NC, USA; 6GlaxoSmithKline, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
